ROS1 and cancer: Tyrosine kinase inhibitors (TKI) are the third generation of small molecule targeted drugs targeting ALK mutations, which can selectively bind the products of ALK and ROS1 fusion driver gene variants, block the activation and transmission of downstream signaling pathways, and thus inhibit the growth and proliferation of cancer cells with these mutations, and play an anti-cancer role